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Abstract
The environmental factors at play in the pathogenesis of type 1 diabetes (T1D) remain enigmatic. Mycobacterium avium
subspecies paratuberculosis (MAP) is transmitted from dairy herds to humans through food contamination. MAP causes an
asymptomatic infection that is highly prevalent in Sardinian T1D patients compared with type 2 diabetes (T2D) and healthy
controls. Moreover, MAP elicits humoral responses against several mycobacterial proteins. We asked whether antibodies
(Abs) against one of these proteins, namely MAP3865c, which displays a sequence homology with the b-cell protein zinc
transporter 8 (ZnT8) could be cross-reactive with ZnT8 epitopes. To this end, Ab responses against MAP3865c were analyzed
in Sardinian T1D, T2D and healthy subjects using an enzymatic immunoassay. Abs against MAP3865c recognized two
immunodominant transmembrane epitopes in 52–65% of T1D patients, but only in 5–7% of T2D and 3–5% of healthy
controls. There was a linear correlation between titers of anti-MAP3865c and anti-ZnT8 Abs targeting these two
homologous epitopes, and pre-incubation of sera with ZnT8 epitope peptides blocked binding to the corresponding
MAP3865c peptides. These results demonstrate that Abs recognizing MAP3865c epitopes cross-react with ZnT8, possibly
underlying a molecular mimicry mechanism, which may precipitate T1D in MAP-infected individuals.
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Introduction
Type 1 diabetes (T1D) is a paradigmatic example of
autoimmune disease stemming from a complex interaction
between genetic and environmental factors [1]. While several
genetic susceptibility loci have been pinpointed, the environmental
factors at play remain boldly elusive. Yet, environmental factors
play a prominent role in T1D pathogenesis, as suggested by the
incomplete (,65%) T1D concordance between monozygotic
twins [2], by migrant studies [3] or by the decreasing weight of
susceptible and protective HLA Class II haplotypes over the last
decades [4].
Among the environmental factors that have been called forth,
viral infections – particularly enteroviruses - have received
overarching attention. While epidemiological studies show a
temporal correlation between enteroviral infections and appear-
ance of anti-islet auto-antibodies (aAbs) [5], investigations using
the NOD mouse model suggest that enteroviral infections may
accelerate rather than initiate T1D progression, as they are
effective only once autoimmune T cells have already accumulated
in the islets [6]. The pathophysiological mechanisms through
which enteroviral infections may favor T1D development include
promoting local islet inflammation, cytolytic effects on b cells and
molecular mimicry [7]. This latter concept has been proposed
based on aminoacid sequence homologies and/or immune cross-
reactivity between viral and b-cell epitopes [8].
The role of bacterial infections as T1D triggers or accelerators
have received comparatively less attention. Mycobacterium avium
subspecies paratuberculosis (MAP) is the causative agent of
paratuberculosis (Johne’s disease), a chronic enteritis that affects
dairy herds [9]. Environmental contamination with MAP is
widespread, as MAP is detected in cattle’s feces, soil, water (where
it survives chlorination), it is shed into milk [10] and is found in
commercially pasteurized dairy preparations [11] and meat
products [12]. Although transmitted to man, MAP infection is
asymptomatic in human carriers and is not therefore regarded as a
zoonosis, nor subjected to eradication in contaminated animals.
Counting ,1.8 million inhabitants, ,3.5 millions sheeps and
approximately two hundred thousand cattle, MAP exposure may
be particularly high in the Western Mediterranean island of
Sardinia, where it is estimated that ,60% of flocks may be
contaminated. Sardinia is also one of the regions with the highest
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exception in the north-south gradient followed by these autoim-
mune diseases.
Although evidence for a cause-effect relationship is lacking,
MAP transmission to humans has long been associated with
Crohn’s disease both in Sardinia [13] and elsewhere [14]. We
have recently proposed that MAP infection may be a potential
candidate environmental trigger also for T1D. Our hypothesis is
based on two key findings. First, MAP infection is highly prevalent
in Sardinian T1D patients. Indeed, MAP DNA can be isolated
from blood in 63% of Sardinian T1D patients, but only in 16% of
healthy controls [15]; the MAP envelope protein MptD can be
detected in the blood of 47.3% Sardinian T1D patients, but in a
smaller proportion of type 2 diabetes (T2D) patients (7.7%) and
healthy controls (12.6%) [16]; and MAP bacilli can be cultured
from blood [16]. Second, this MAP infection triggers a specific
humoral response, as Sardinian T1D patients display high
frequencies of antibodies (Abs) against mycobacterial proteins
(heparin-binding hemagglutinin, glycosyl transferase) [17], whole
MAP lysates (70% Ab+ T1D patients vs 7.6% Ab+ healthy
controls) [16] and the MAP-specific proteins MptD (MAP3733c)
and MAP3738c when compared to T2D and healthy controls
[16].
More recently, we have also documented an association
between MAP DNA detected in blood and MS in Sardinian
patients [18]. Thirty-two percent of MS patients, but only 2% of
healthy controls, also harbored Abs recognizing the MAP2694
protein, which displays a 33% homology with the C region of the
T-cell receptor (TCR) c chain expressed by cd T cells. The cd T-
cell subset patrols gut epithelial barriers and has been called into
question in clearing infectious pathogens, most notably mycobac-
teria [19]. As depletion of cd T cells in murine models of
experimental autoimmune encephalomyelitis leads to disease
development or exacerbation [20], we proposed that anti-
MAP2694 Abs may cross-react with the cd TCR, possibly leading
to cd T-cell depletion triggering increased MS susceptibility [18].
Another MAP protein, namely MAP3865c, displays a sequence
homology with the b-cell antigen zinc transporter 8 (ZnT8), which
is targeted by aAbs in T1D patients [21]. In light of this homology,
we here sought to determine whether Abs recognizing MAP3865c
are cross-reactive with ZnT8 epitopes. We show that Sardinian
T1D patients specifically mount anti-MAP3865c Ab responses.
Two immunodominant Ab epitopes were identified within the
MAP3865c sequence and shown to be cross-reactive with the
homologous ZnT8 sequences, raising the possibility of a molecular
mimicry between mycobacterial and b-cell epitopes.
Results
Anti-MAP3865c Abs are highly prevalent in Sardinian T1D
patients, but not in T2D patients
The purified MAP3865c-MBP fusion protein was first used to
screen by ELISA for the presence of serum anti-MAP3865c Abs.
As shown in Fig. 1A, 29.4% of T1D patients displayed serum
reactivity against MAP3865c compared to 6.4% of healthy
controls (AUC 0.68, p=0.014). This reactivity was specific of
T1D patients, as it was not significantly different between T2D
patients and controls (Fig. 1B; 3.6% vs 2.9%; AUC 0.55;
p=0.396).
Since the MAP3865c protein was fused with MBP, Ab+ and
Ab-negative sera were tested against the LacZ-MBP control to
exclude potential MBP-specific reactivities. A difference in Ab
reactivity between Ab+ and Ab-negative sera and between T1D
and healthy subjects was only observed when testing with the
MAP-MBP protein, while the LacZ-MBP protein did not
discriminate any positive sample using the same sera (Fig. 2A).
The ELISA assay employed displayed good reproducibility. For
determination of intra-assay variability, a serum with MAP3865c
Ab reactivity near the cut-off values was tested 20 times in a single
experiment, giving a coefficient of variation (CV) of 2.8%.
(Fig. 2B). The same serum tested in 4 separate experiments
yielded an inter-assay CV of 7.4% (Fig. 2B).
As previously reported [15], the presence of MAP-specific IS900
DNA was also more prevalent among T1D patients (55.9%) than
among T2D and healthy controls (7.0% and 20.0%, respectively;
p,0.001). However, there was no correlation between positivity
for anti-MAP3865c Abs and IS900 DNA (Table 1), although the
frequency of Ab+ T1D patients was higher in the IS900 DNA+
group (7/34 ¸20.6% vs 3/34, 8.8%).
Anti-MAP3865c Abs recognize an immunodominant
transmembrane region homologous to ZnT8
Scanning of the MAP3865c aminoacid sequence unraveled a
27.5% sequence identity with the human b-cell protein ZnT8
(Slc30A8) (Fig. 3A). To further explore the significance of this
homology, we focused our analysis on one of the highly conserved
regions (41.2% aminoacid identity) corresponding to the
Figure 1. Prevalence of anti-MAP3865c Abs in Sardinian T1D and T2D patients. Sera were tested for their reactivity against plate-coated
MAP3865c-MBP fusion protein. Ab distribution is shown for T1D (A) and T2D (B) patients compared to healthy controls. Dotted lines indicate the cut-
off for positivity used in each assay, as calculated by ROC analysis. The percent fraction of Ab+ sera is indicated on top of each distribution, while bars
indicate the corresponding median 6 interquartile range. AUC and p values are given in the top right corner. Figures show representative
experiments out of three performed.
doi:10.1371/journal.pone.0026931.g001
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are located in one of the 6 membrane-spanning domains of the
two proteins (Fig. 3B).
Two nonamer peptides covering this region were synthesized:
MAP3865c125–133 (MIAVALAGL) and MAP3865c133–141
(LAANFVVAL). Competition assays demonstrated that these
epitopes are immunodominant Ab targets within the full-length
MAP3865c protein, as sera pre-adsorbed with these peptides,
either alone or in combination, were capable of blocking binding
to the MAP3865c-MBP fusion protein, to a similar extent to what
observed when pre-adsorbing sera with the MAP3865c-MBP
protein itself (Fig. 4).
The homologous ZnT8 peptides corresponding to these
MAP3865c sequences were further synthesized: ZnT8178–186
(MIIVSSCAV) and ZnT8186–194 (VAANIVLTV). Serum Ab
reactivity against these four MAP3865c and ZnT8 peptides was
further tested using the same ELISA assay. Also in this case, a
significant difference in the frequency of Ab+ sera was observed
between T1D and healthy subjects (Fig. 5). The homologous
MAP3865c125–133 and ZnT8178–186 peptides (Fig. 5A–B) were
recognized by 65.4% and 68.0% of T1D patients, but only in
4.2% of healthy controls (AUC 0.85 and 0.86, respectively;
p,0.0001 for both). This serum Ab reactivity was also observed
for the MAP3865c133–141 and ZnT8186–194 peptides (Fig. 5C–D),
as 51.6% and 55.6% of T1D patients were Ab+, respectively,
compared to 4.2% of healthy controls (AUC 0.75 and 0.79;
p=0.0003 and p,0.0001, respectively). As observed for the whole
MAP3865c protein, this reactivity was specific of T1D patients, as
it was not observed among T2D subjects (Fig. 6).
Comparison of Ab+ and Ab-negative T1D patients (Table 2)
showed that anti-MAP3865c Ab+ patients had a significantly
shorter disease duration than Ab-negative pairs (10.967.7 vs
17.9610.0; p=0.025). Similar trends were observed when
comparing T1D patients harboring or not Abs against
MAP3865c125–133 (12.668.8 vs 17.2610.0; p=0.068) and its
homologous ZnT8178–186 (12.668.8 vs 18.0610.0; p=0.068), but
not for Abs against MAP3865c133–141 (13.268.6 vs 17.5610.4;
p=0.170) or its homologous ZnT8186–194 (13.8612.3 vs 17.569.5;
p=0.296). A trend towards an older age at T1D diagnosis was also
observed in patients positive for Abs against MAP3865c (22.969.6
vs 16.3610.0; p=0.072).
Anti-MAP3865c and anti-ZnT8 Abs recognizing
homologous sequences are cross-reactive
The similar frequencies of Abs recognizing MAP3865c and
ZnT8 homologous regions among T1D patients (65.4–68.0% and
51.6–55.6%, respectively; Fig. 5) suggest that Abs targeting these
epitopes could be cross-reactive. Indeed, there was a high degree
of correlation between the titers of Abs recognizing MAP3865c
and ZnT8 homologous sequences in both T1D patients and
healthy controls (Fig. 7A–B; r
2=0.74 for MAP3865c125–133 vs
ZnT8178–186 and r
2=0.58 for MAP3865c133–141 vs ZnT8186–194;
p,0.0001). This correlation was maintained when the analysis was
restricted to either T1D patients or healthy controls (data not
shown). This demonstrates that anti-MAP3865c and anti-ZnT8
Abs recognizing homologous sequences segregate within the same
sera. The same was true for Ab reactivities against the two
neighboring regions MAP3865c125–133 and MAP3865c133–141 and
for ZnT8178–186 and ZnT8186–194 (Fig. 7C–D; r
2=0.67 and 0.74,
respectively; p,0.0001), suggesting that recognition of these
epitopes stems from an immune response against the whole
MAP3865c/ZnT8 transmembrane region to which they belong.
To verify whether co-segregation of these reactivities was due to
Ab specificities cross-reacting between each other, competition
experiments were performed. Anti-MAP3865c125–133-positive and
-negative sera were pre-adsorbed overnight with different peptides,
then subjected to ELISA on MAP3865c125–133-coated plates
(Fig. 8A). While a control peptide did not cause any decrease in
signal, both MAP3865c125–133 and its homologous ZnT8178–186
peptide strongly inhibited the MAP3865c125–133 reactivity to a
similar extent (57–89%). The same observation was repeated with
Figure 2. Validation of anti-MAP3865c Ab assays. (A) Reactivity against the MAP-MBP fusion protein is MAP-specific. Ab+ and Ab-negative sera
from T1D and healthy donors were challenged either with the MAP-MBP fusion protein (as in Fig. 1) or with a LacZ-MBP control protein. The dotted
line indicates the cutoff for positivity. (B) Intra- and inter-assay variability of MAP3865c ELISA Ab assays. For intra-assay variability (white bars), the
same serum was tested in 20 replicate wells; bars show readouts of each single well. CV is 2.8%. For inter-assay variability (grey bars), the same serum
was tested in 4 separate experiments; bars show mean 6 SEM of triplicate wells from each experiment. CV is 7.4%.
doi:10.1371/journal.pone.0026931.g002
Table 1. Prevalence of MAP-specific IS900 DNA and of anti-
MAP3865c Abs in the peripheral blood of T1D patients
(n=34).
IS900 PCR+ IS900 PCR2
MAP3865c Ab+ 20.6% 8.8%
MAP3865c Ab2 52.9% 17.7%
doi:10.1371/journal.pone.0026931.t001
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66%) upon serum pre-adsorption with either MAP3865c133–141
or its homologous ZnT8186–194 (Fig. 8B). Taken together, these
results demonstrate that anti-MAP and anti-ZnT8 Abs targeting
homologous membrane-spanning sequences are cross-reactive.
Discussion
Building up on our previous reports documenting a high
prevalence of MAP infection and sero-reactivity in Sardinian T1D
patients [15,16,17,22], we here demonstrate that the MAP3865c
protein is a target of Ab responses that cross-react with
Figure 3. Homology between MAP3865c and ZnT8 proteins. (A) Aminoacid sequence alignment of ZnT8 (Slc30A8) and MAP3865c proteins.
Conserved aminoacid residues are highlighted in yellow within the MAP3865c sequence and listed in bold below the two sequence alignment rows.
The other color codes refer to the ZnT8 protein structure shown in (B): sequences highlighted in green belong to the 3 intra-luminal loops; the
sequence in red belongs to the fourth transmembrane domain, while those in blue belong to the other transmembrane regions; sequences not
highlighted fall within the 4 extra-luminal fragments. Dotted rectangles show the MAP3865c125–133/ZnT8178–186 and MAP3865c133–141/ZnT8186–194
peptides studied in subsequent experiments. The topology of the ZnT8 protein is also shown in panel (B), where the 3 intra-luminal loops (in green)
become extracellularly exposed once the insulin granule is released. Conversely, the 4 extra-luminal domains (in black) are exposed to the cytosol and
remain intracellular upon insulin exocytosis.
doi:10.1371/journal.pone.0026931.g003
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membrane-spanning channel which endows MAP with the ability
to transport cations through the membrane, an important feature
associated with intracellular survival of mycobacteria [23]. ZnT8 is
a 369 aminoacid protein which belongs to the cation diffusion
facilitator family of ZnT (Slc30) proteins. It displays a remarkably
similar structure and function, allowing Zn
2+ to accumulate in the
insulin granules of pancreatic b cells. Zn
2+ cations are essential to
form hexavalent insulin storage crystals and, eventually, for
effective insulin secretion [24]. Most of the 71 aminoacid
difference in length between MAP3865c and ZnT8 is made up
by the first extra-luminal domain, which is much shorter for
MAP3865c (Fig. 3B).
To look for potential cross-reactive Ab epitopes, we focused our
analysis on a trasmembrane region of high homology. Ab
reactivities against peptide sequences of this region were even
more prevalent in T1D patients than those against the whole
MAP3865c protein, perhaps reflecting masking of these hydro-
phobic epitopes in the solubilized MAP3865c protein. Important-
ly, Abs against this membrane-spanning epitopes would not be
detected by conventional anti-ZnT8 aAb assays, which employ a
fusion protein combining the 4 extra-luminal domains of ZnT8
[21]. Other regions of high homology are mostly located in these
extra-luminal domains, raising the possibility that other cross-
reactive epitopes may be recognized by other Abs, including
conventional anti-ZnT8 aAbs. Of further note, the transmem-
brane region identified here does not comprise the polymorphic
ZnT8 R/W variant at position 325, which is located in the last
extra-luminal domain, thus making it unlikely that the ZnT8
genetic background may shape these Ab reactivities, as described
for conventional anti-ZnT8 aAbs [25].
The intestinal localization of MAP infection may also favor
cross-reactivity with Abs and T cells recognizing ZnT8. Indeed,
Figure 4. Ab reactivities against the MAP3865c protein are
inhibited by MAP3865c125–133 and MAP3865c133–141 peptides.
Ab+ and Ab-negative sera from T1D patients were pre-incubated
overnight with saturating concentrations (5.5 mM) of MAP3865c125–133,
MAP3865c133–141, the two peptides in combination, MAP3865c-MBP
fusion protein and control or no peptide. Their reactivity on MAP3865c-
MBP-coated ELISA plates was subsequently tested. Bars depict means 6
SEM of triplicate wells and results are representative of three separate
experiments.
doi:10.1371/journal.pone.0026931.g004
Figure 5. Prevalence of Abs against homologous MAP3865c and ZnT8 epitopes in T1D patients. Prevalence of Abs against
MAP3865c125–133 (A) and its homologous ZnT8178–186 (B); and against MAP3865c133–141 (C) and its homologous ZnT8186–194 (D) in T1D and healthy
subjects. Data representation is the same as in Fig. 1.
doi:10.1371/journal.pone.0026931.g005
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lymph nodes [26], which also drain intestinal tissues [27]. Epitope
mimicry and spreading may be further favored by high precursor
frequencies of ZnT8-reactive naı ¨ve T cells. As ZnT8 has not been
found expressed by medullary thymic epithelial cells [28], negative
selection of ZnT8-reactive T cells may be ineffective. Thus,
tolerance to ZnT8 may heavily rely on peripheral mechanisms
such as immune ignorance, which may be readily overcome by
MAP infection. The intestinal localization of MAP infection may
also give reason for the lack of correlation between MAP IS900
DNA and Ab detection. Not all MAP-infected individuals may
mount systemic Ab responses detectable in blood, or they may
develop Abs against other MAP antigens.
It is still premature to conclude whether MAP3865c-ZnT8
cross-reactivity implies an epitope mimicry phenomenon initiating
or precipitating T1D. To this end, three key points remain to be
addressed. First, MAP3865c-ZnT8 cross-reactivity was document-
ed at the Ab level, but we did not yet explore potentially cross-
reactive T-cell responses. CD4+ T-cell priming is an early event in
the autoimmune cascade, providing help to B lymphocytes for
differentiating into Ab-secreting plasma cells. Importantly, none of
the ZnT8-derived CD4+ T-cell epitopes recently described [29]
map to the Ab-targeted region here identified. Moreover, CD8+ T
cells are additional key players in b-cell autoimmunity [30].
Second, is MAP infection and sero-reactivity already present
before or at T1D onset, i.e. in at-risk and new-onset T1D subjects?
Once T1D established, we cannot resolve whether MAP infection
preceded or followed T1D onset, pointing either to a causal
relationship with disease or to a consequence thereof. The
Figure 6. Prevalence of Abs against homologous MAP3865c and ZnT8 epitopes in T2D patients. Prevalence of Abs against
MAP3865c125–133 (A) and its homologous ZnT8178–186 (B); and against MAP3865c133–141 (C) and its homologous ZnT8186–194 (D) in T2D and healthy
subjects. Data representation is the same as in Fig. 1.
doi:10.1371/journal.pone.0026931.g006
Table 2. T1D duration and age at T1D diagnosis in Ab+ and
Ab-negative T1D patients.
T1D duration (yrs) Age at T1D diagnosis (yrs)
MAP3865c Ab+ 10.967.7 22.969.6
MAP3865c Ab2 17.9610.0 16.3610.0
p 0.025 0.072
MAP3865c125–133 Ab+ 12.668.8 19.8611.0
MAP3865c125–133 Ab2 17.2610.0 17.169.8
p 0.068 0.340
ZnT8178–186 Ab+ 12.668.8 19.8611.0
ZnT8178–186 Ab2 18.0610.0 16.769.8
p 0.068 0.340
MAP3865c133–141 Ab+ 13.268.6 20.8610.2
MAP3865c133–141 Ab2 17.5610.4 16.6610.5
p 0.170 0.229
ZnT8186–194 Ab+ 13.8612.3 20.1614.3
ZnT8186–194 Ab2 17.569.5 16.669.3
p 0.296 0.347
T1D patients whose Ab reactivities are shown in Figures 1 and 5 were
compared using the Mann-Whitney U test. Mean 6 SD are shown.
doi:10.1371/journal.pone.0026931.t002
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duration makes the first hypothesis more attractive. It may be
argued that anti-ZnT8 aAbs typically appear later than insulin
aAbs in at-risk children [21]. This could suggest that MAP
infection generating cross-reactive anti-ZnT8 aAbs is a late event.
However, this would rule out an initiating effect, but not a
precipitating contribution to T1D development once autoimmu-
nity has been initiated, as proposed for coxsackievirus infections
[6,7]. Moreover, the T1D patients studied here were adults, who
are rarely insulin aAb+ and more frequently harbor anti-GAD
and/or anti-IA-2 aAbs, which do not clearly preceed anti-ZnT8
[21]. Of further note, the relationship between the classical anti-
ZnT8 aAbs and MAP cross-reactivity remains to be established, as
the cross-reactive epitopes here identified are located outside the
regions recognized by these aAbs. It is thus possible that early
MAP infection may initially ignite immune responses against this
transmembrane region, to only later spread to the extra-luminal
epitopes covered by anti-ZnT8 aAb assays.
Third, it is well established that T cells are the key pathogenic
effectors of T1D, while aAbs only play an accessory role which is
matter of debate [31]. Therefore, to definitely prove a causal
relationship beyond the correlation between MAP infection and
T1D, mouse studies should be performed to document that MAP
infection, MAP3865c immunization and/or MAP-reactive T cells
induce disease. These experiments are difficult to perform for a
number of reasons. The presence of ZnT8-specific aAbs or T cells
has not yet been reported in NOD mice. Moreover, the Ab
epitopes here identified are poorly conserved in the mouse. Of
further note, we cannot discount the possibility of a direct
cytotoxic effect of anti-MAP3865c/ZnT8 cross-reactive Abs
through binding to b cells. The transmembrane location of these
epitopes may allow Abs to exert an agonistic or antagonistic effect
on Zn
2+ transport through the ZnT8 channel, possibly impinging
on the b-cell secretory capacity.
The majority – but not all [32] – of studies on Sardinian
migrants suggests a predominant weight of genetic factors on T1D
pathogenesis, as disease incidence in the hosting region remains
similar to that of Sardinia [33]. This observation is at variance
with most T1D migrant studies [3] and with comparisons of T1D
incidence between neighboring regions of uniform genetic
background and diverse environmental exposure [34], which
instead point to a prominent role of environmental factors. The
possible involvement of MAP in the pathogenesis of Sardinian
T1D may reconcile this conundrum. As MAP has been shown to
pass into human breast milk [35], children born outside Sardinia
from Sardinian mothers could still be more exposed to MAP
infection. Moreover, Sardinian migrants frequently maintain
regular interactions with their homeland relatives, including
exchange of regional dairy and meat products which may
contribute in maintaining MAP exposure.
Another open question is whether our current observations are
specific to the Sardinian population or can be replicated
Figure 7. Correlation between titers of MAP3865c- and ZnT8-reactive Abs recognizing different epitopes. Correlations are shown
between titers of Abs recognizing (A) MAP3865c125–133 and its homologous ZnT8178–186 epitope; (B) MAP3865c133–141 and its homologous ZnT8186–194
epitope; (C) MAP3865c125–133 and its consecutive MAP3865c133–141 epitope; (D) ZnT8178–186 and its consecutive ZnT8186–194 epitope. Each circle
represents the titers of one T1D or healthy donor.
doi:10.1371/journal.pone.0026931.g007
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Sardinia, contamination of food products with MAP has been
documented worldwide. While we are not aware of studies
performed in other areas at very high T1D incidence such as
Scandinavia, studies conducted in UK document a MAP
prevalence in herds and dairy products similar to what found in
lower incidence countries [12]. Thus, the environmental preva-
lence of MAP does not systematically parallel that of T1D,
suggesting that other factors may be at play. As suggested for
enteroviral infections [6,7], timing of MAP infection may be one
such factor, making epitope mimicry effective only once an
inflammatory milieu is established, once b-cell autoimmunity is
initiated and/or once a critical mass of ZnT8-reactive T cells have
already accumulated. The chronic nature of MAP infection may
also perpetuate availability of cross-reactive epitopes. Ultimately,
the interaction between MAP environmental exposure and a
susceptible genetic background such as the Sardinian one may be
critical, as children whose parents have migrated to Sardinia do
not acquire a higher T1D risk [36]. Indeed, the gene pool of
Sardinians is highly distinct from that of all other Mediterranean
regions, probably reflecting a genetic drift entrenched over
centuries by geographical isolation, epidemic misfortunes and
endogamy [37]. Genetic susceptibility may be conferred by
polymorphic loci involved in clearance of intracellular bacteria,
such as the SLC11A1 locus (previously known as NRAMP1).
SLC11A1 polymorphisms have been associated with T1D in
Sardinian [38] and Japanese [39] patients and in NOD mice [40],
as well as with susceptibility to mycobacterial infections [41].
SLC11A1 is a transporter of divalent cations in the late
endosomal/lysosomal compartments of phagocytes [42]. Trans-
port of divalent cations contributes to enhanced phagosomal
acidification [43], thus impairing survival of intracellular patho-
gens [42] and modifying processing and presentation of certain
epitopes, including b-cell derived ones [43]. Another intriguing
observation is that the long-standing diatribe as to whether early
childhood exposure to cow’s milk predisposes to islet Ab
seroconversion and T1D has remained unsettled [44,45]. MAP
contamination of milk supplies and the interaction between MAP
environmental exposure and a susceptible genetic ground may
offer an alternative interpretation.
Finally, the individual genetic background over which MAP
exposure builds up may dictate susceptibility to other autoimmune
and inflammatory diseases such as MS and Crohn’s disease, which
have also been associated with MAP infection in Sardinia [13,18]
and elsewhere [14]. Further investigations outside Sardinia and
comprehensive dissection of the groove between genetic and
environmental factors will be critical in deciphering the signifi-
cance of these findings in T1D pathogenesis.
Materials and Methods
Patient and control serum samples
T1D patients (n=34; mean age 34.567.7 years, mean age at
onset 17.5610.2 years, mean T1D duration 16.869.9 years) and
T2D patients (n=56; mean age 64.868.6 years, mean age at onset
56.469.2 years, mean T2D duration 8.565.3 years) diagnosed
according to the American Association of Diabetes criteria [46]
and healthy blood donors (n=63) age-matched with T1D patients
(mean age 38.5612.0 years; p=0.102) were recruited at the
University Hospital of Sassari. Written informed consents were
obtained before blood drawing and the study was approved by the
University Ethics Committee. Serum samples were processed as
previously described [16].
Construction of the pMAL-MAP3865c expression vector
MAP DNA was extracted with the detergent cetyltrimethylam-
monium bromide (Sigma). The full-length MAP3865c gene was
amplified by PCR from the MAP DNA ATCC43015 with a sense
primer (59-GCGCGAATTCATGGGCGCCGGCCACAACCA-
CAC-39) and an antisense primer (59- GCGCCTGCAGTCAT-
CAGAAGCTGTCGGAGCACTC-39), where underlined se-
quences are EcoRI and PstI restriction sites, respectively. The
MAP3865c coding sequence was cloned into pMALc2X (New
England Biolabs) next to a maltose-binding protein (MBP)
sequence, and the ligation mix was used to transform E. coli
K12 TB1 competent cells. Transformants were screened by
plating the electroporated K12 TB1 cells on rich medium (10 g/l
tryptone, 5 g/l yeast extract, 5 g/l NaCl) supplemented with
ampicillin (100 mg/ml). The coding sequence of the cloned
Figure 8. Ab reactivities against MAP3865c epitopes are
inhibited by the homologous ZnT8 epitopes. (A) Ab+ and Ab-
negative sera from T1D patients were pre-incubated overnight with
saturating concentrations of MAP3865c125–133 (white bars), ZnT8178–186
(hatched bars), control (grey bars) or no peptide (black bars) and their
reactivity on MAP3865c125–133-coated ELISA plates subsequently tested.
(B) The same sera were preincubated with MAP3865c133–141 (white
bars), ZnT8186–194 (hatched bars), control (grey bars) or no peptide
(black bars) and their reactivity on MAP3865c133–141-coated ELISA plates
subsequently tested. Bars depict means 6 SEM of triplicate wells and
results are representative of two separate experiments.
doi:10.1371/journal.pone.0026931.g008
Antibodies Cross-Reactive with ZnT8
PLoS ONE | www.plosone.org 8 October 2011 | Volume 6 | Issue 10 | e26931MAP3865c gene fully matched the published sequence of the
MAP3865c gene of M. paratuberculosis K10 (GenBank accession
number: NC002944).
MAP3865c protein expression and purification
E. coli TB1 cells harboring the expression plasmid were grown at
37uC and a single colony was used to inoculate rich medium
containing 1 g/l ampicillin and 2 g/l glucose. MAP3865c-MBP
fusion protein expression was induced by addition of 0.3 mM
isopropyl-b-D-thiogalactopyranoside (Sigma). After 2 h, cells were
harvested, resuspended in 20 ml of column buffer (20 mM Tris-
HCl, 200 mM NaCl, 1 mM ethylenediaminetetraacetic acid
(EDTA), 1:100 Sigma protease inhibitor cocktail) and frozen at
220uC. The following day, cells were lysed by sonication. Debris
were removed by centrifugation, supernatants were diluted 1:5
with column buffer, loaded on a column charged with amylose
resin (New England Biolabs) and washed 5 times. The fusion
protein was eluted with column buffer containing 10 mM maltose.
The MAP3865c-MBP fusion protein migrated at the expected
molecular mass of 72.5 kD in sodium dodecyl sulfate polyacryl-
amide gel electrophoresis.
Peptides
Peptides MAP3865c125–133 (MIAVALAGL) and MAP3865c133–
141 (LAANFVVAL) along with their respective homologous peptides
ZnT8178–186 (MIIVSSCAV) and ZnT8186–194 (VAANIVLTV) were
synthesized at .85% purity (GL Biochem). Conserved aminoacid
residues are underlined. Stock solutions (10 mM in dimethyl
sulfoxide) were stored in single-use aliquots at 280uC.
Enzymatic immunoassay
An indirect enzyme-linked immunosorbent assay (ELISA) were
set up to detect Abs specific for MAP3865c protein and peptides.
Ninety-six-well Nunc immunoplates were coated overnight at 4uC
with 5 mg/ml of recombinant MAP3865c-MBP fusion protein or
10 mg/ml of peptides diluted in 0.05 M carbonate–bicarbonate
buffer, pH 9.5 (Sigma). Plates were then blocked for 1 h at room
temperature with 5% non-fat dried milk (Sigma) and washed twice
with phosphate-buffered saline (PBS) containing 0.05% Tween-20
(PBS-T). Serum samples were subsequently added at 1:100
dilution in PBS-T for 2 h at room temperature. After 5 washes
in PBS-T, 100 ml of alkaline phosphatase-conjugated goat anti-
human immunoglobulin G polyclonal Ab (1:1000; Sigma) was
added for 1 h at room temperature. Plates were washed again 5
times in PBS-T and para nitrophenylphosphate (Sigma) added as
substrate for alkaline phosphatase. Plates were incubated at 37uC
in the dark for 3–6 min and the absorbance at 405 nm read on a
VERSATunable Max microplate reader (Molecular Devices).
Negative control wells were obtained by incubation of immobi-
lized protein or peptides with secondary Ab alone, and their mean
values subtracted from all samples. Positive control sera were also
included in all experiments. Results are expressed as means of
triplicate 405 nm optical density (OD) values.
Competition assays
Competition assays were performed by pre-incubating sera
o v e r n i g h ta t4 uC with saturating concentrations (5–20 mM, titrated
for each individual serum) of MAP peptides, the corresponding ZnT8
peptides, irrelevant peptide (MAP3865c211–217, ILSESSP), no
peptide, or MAP3865c-MBP fusion protein, as previously described
[47]. Sera were then subjected to ELISA on plates coated with
MAP3865c-MBP, MAP3865c125–133 or MAP3865c133–141,a sa b o v e .
MAP IS900 PCR
The presence of MAP-specific DNA in blood samples was
detected by PCR amplification of IS900 sequences, as previously
described [13].
Statistical analyses
Receiver operator characteristic (ROC) curves were used to
score the performance of each single ELISA in discriminating
T1D or T2D patients from healthy controls. AUC was calculated
assuming a non-parametric distribution of results. Thus, an AUC
of 1.0 would indicate that the assay achieved 100% accuracy in
identifying patients; an AUC of 0.5 would indicate that the assay
gave no difference between patients and controls; and an AUC of
0 would indicate that the assay gave a positive result for controls
and a negative result for patients. The cut-off for positivity in each
assay was set at $93% specificity (i.e. Ab+ healthy controls #7%)
and the corresponding sensitivity (i.e. percent of Ab+ patients)
calculated accordingly. Clinical characteristics of Ab+ and Ab-
negative patients were compared using the Mann-Whitney U test.
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